New device aims to improve safety in heart valve replacement

NCT ID NCT07205341

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study is testing a new device called HemoCept that measures blood volume and heart efficiency during trans-aortic valve replacement (TAVR) surgery for aortic stenosis. The study will enroll 20 adults aged 18-80 who need TAVR. Researchers want to see if the device's readings match standard heart measurements taken before and after the procedure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

HemoCept device

What this could lead to

If successful, this could lead to a new way to monitor blood volume and heart function during TAVR surgery, potentially improving patient safety.

What could go wrong

This is a very small pilot study with only 20 people, so results may not apply to everyone. The device is still experimental and may not work as hoped.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AORTIC VALVE STENOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aortic valve stenosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Boulder Heart

    RECRUITING

    Boulder, Colorado, 80303, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••